Mon, Sep 22, 2014, 8:20 AM EDT - U.S. Markets open in 1 hr 10 mins


% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • nomad_celcius12 nomad_celcius12 Dec 18, 2012 10:56 AM Flag

    The only red on my screen!

    I referred this board to ARQL a week or so ago. Chart is uber-bullish :-)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "I referred this board to ARQL a week or so ago. Chart is uber-bullish :-)" It's not uncommon for biotechs to recover after getting pounded by a negative binary event. I traded DVAX after their AdComm and you saw the front end of the KERX debacle. ARQL caught a double whammy, first one pivotal lung cancer trial was suspended for safety and then their second trial was shut down early for efficacy. The current plan is to pursue refractory HCC overexpressing cMET. InterestinglyARQL's trial may overlap with a planned Comet trial in refractory HCC, likely to not include the cMET limitation. I realize your not looking to the long term and plan a short term trade, but I still see problems at ARQL. Their lead drug is faltering and they will need to raise money at some point in the not too distant future.

1.70-0.02(-1.16%)Sep 19 4:15 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.